Klein D M, Witek-Janusek L
Dimens Crit Care Nurs. 1992 Mar-Apr;11(2):75-89. doi: 10.1097/00003465-199203000-00007.
Septic shock, with its associated high morbidity and mortality, has long been a challenge to the critical care nurse. A promising new development in the treatment of this condition is the use of monoclonal antibodies to inactivate two prime mediators that induce the cascade of events that culminate in septic shock and multiple organ failure: bacterial endotoxin and tumor necrosis factor (TNF). The effectiveness of this immunotherapy depends on its timely administration, which necessitates the early identification of sepsis.
感染性休克及其相关的高发病率和死亡率，长期以来一直是重症监护护士面临的挑战。治疗这种疾病的一个有前景的新进展是使用单克隆抗体来使两种主要介质失活，这两种介质会引发一系列最终导致感染性休克和多器官功能衰竭的事件：细菌内毒素和肿瘤坏死因子（TNF）。这种免疫疗法的有效性取决于其及时给药，这就需要早期识别败血症。
